Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of August 2026. The report details a Registered Direct Offering completed on August 13, 2026, wherein the Company issued 44,052,862 ordinary shares to institutional investors.
Key Financial Metrics
- Offering Proceeds: Approximately $20.0 million in net proceeds (before offering expenses).
- Share Price: $0.454 per ordinary share.
- Shares Issued: 44,052,862 ordinary shares.
- Post-Offering Outstanding Shares: 95,417,382 ordinary shares.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for existing debt or liquidity ratios, though proceeds are designated for working capital.
Material Changes
The primary material change is the capital increase resulting from the Registered Direct Offering. The Company amended its Articles of Association on August 13, 2026, to reflect the issuance of 44,052,862 new shares. This transaction significantly increased the total number of outstanding shares to 95,417,382.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use the net proceeds for working capital and general corporate purposes, specifically to fund product development efforts and expand commercialization activities.
Transaction Structure: The shares were offered directly to investors without a placement agent, underwriter, broker, or dealer. The offering was conducted pursuant to a shelf registration statement on Form F-3.
Risks and Contingencies: The filing notes that the summary of the Securities Purchase Agreements is subject to the full agreement filed as Exhibit 10.1. No specific new risks or contingencies were detailed in the text beyond standard legal disclaimers regarding the legality of the offering.
Investor Verification Checklist
- Verify the exact amount of offering expenses deducted from the gross proceeds to determine final net cash inflow.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants, redemption rights, or registration rights granted to investors.
- Confirm the dilution impact on existing shareholders given the increase to 95,417,382 outstanding shares.
- Assess the timeline for the deployment of the $20.0 million into product development and commercialization.